Company news
Camurus Ab (OMXSTO:CAMX) news
Camurus Ab news releases on 6ix. Latest, Jul 17, 2026: Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
Press releases & updates
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
July 17, 2026
Camurus' Interim Report Second Quarter 2026
July 15, 2026
Change in number of shares and votes in Camurus
June 30, 2026
Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly
June 10, 2026
Camurus : AGM Minutes 2026 (agm minutes 2026)
June 1, 2026
Camurus : CEO Presentation (ceo presentation)
May 29, 2026
Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2026/2029
May 28, 2026
Camurus' Interim Report January-March 2026
May 12, 2026
Camurus : Proposal by the Board of Directors on the implementation of a Performance Share Plan 2026/2029
April 29, 2026
Camurus : Proposal by the BoD on authorization for the Board of Directors to resolve on issues of new shares and convertibles
April 29, 2026
Camurus : Proposal by the Board of Directors on authorization for the Board of Directors to resolve on acquisition and transfer of own shares
April 29, 2026
Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
February 17, 2026
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
January 9, 2026
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
November 10, 2025
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
August 28, 2025
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
July 1, 2025
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
June 18, 2025
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
June 3, 2025
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
April 25, 2025